FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now?
Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...
Bristol Myers price target raised to $61 from $57 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Bristol Myers (BMY) to $61 from $57 and keeps a Market Perform ...
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Bristol Myers price target raised to $39 from $36 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Bristol Myers (BMY) to $39 from $36 and keeps an Underweight rating on the shares ...
Buy, Sell, Or Hold BMY Stock?
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
Bristol-Myers upgraded at Leerink after AbbVie setback
Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...
AbbVie reveals schizophrenia setback
Pharmaceutical company AbbVie announced that an experimental schizophrenia drug that was key to its $8.7 billion acquisition ...
BioPharma Dive4d
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Morningstar4d
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Related: Bristol Myers Squibb's stock jumps on schizophrenia-drug approval ... pointing to the recent Food and Drug Administration approval of the company's schizophrenia drug Cobenfy. AbbVie's ...